share_log

Capital Increase in Genmab as a Result of Employee Warrant Exercise

Capital Increase in Genmab as a Result of Employee Warrant Exercise

行使員工認股權證導致Genmab的資本增加
GlobeNewswire ·  05/07 14:27

Company Announcement

公司公告

COPENHAGEN, Denmark; May 7, 2024 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 6,959 shares as a consequence of the exercise of employee warrants.

丹麥哥本哈根;2024 年 5 月 7 日 — Genmab A/S 納斯達克股票代碼:GMAB)將通過行使員工認股權證將其股本增加6,959股。

The increase is effected without any preemption rights for the existing shareholders of the company or others. The shares are subscribed in cash at the following price per share of nominally DKK 1:

此次增持是在公司或其他人的現有股東沒有任何優先購買權的情況下實現的。股票以以下每股價格以現金認購,名義上爲1丹麥克朗:

2,171 shares at DKK 1,025.00,
2,790 shares at DKK 1,032.00,
98 shares at DKK 1,161.00,
729 shares at DKK 1,334.50,
343 shares at DKK 1,362.50,
549 shares at DKK 1,408.00,
179 shares at DKK 1,432.00, and
100 shares at DKK 1,615.00.

2,171股股票價格爲1,025.00丹麥克朗,
2,790股股票,價格爲1,032.00丹麥克朗,
98股股價爲1,161.00丹麥克朗,
729股股票價格爲1,334.50丹麥克朗,
343股股票,價格爲1,362.50丹麥克朗,
549股股票,價格爲1,408.00丹麥克朗,
179股股票價格爲1,432.00丹麥克朗,以及
100股股票,價格爲1,615.00丹麥克朗。

Proceeds to the company are approximately DKK 7.8 million. The increase corresponds to approximately 0.01% of the company's share capital.

該公司的收益約爲780萬丹麥克朗。增幅約相當於公司股本的0.01%。

The new shares are ordinary shares without any special rights and are freely transferable negotiable instruments. The new shares give rights to dividends and other rights in relation to the company as of subscription. The new shares will be listed on Nasdaq Copenhagen after registration with the Danish Business Authority. The capital increase is expected to be finalized shortly.

新股是沒有任何特殊權利的普通股,是可自由轉讓的流通票據。新股賦予股息權和其他自認購之日起與公司有關的權利。在丹麥商業管理局註冊後,新股將在哥本哈根納斯達克上市。增資預計將很快完成。

Pursuant to section 32 of the Danish Capital Markets Act No. 198 of February 26, 2024, it is hereby announced, that the total nominal value of Genmab A/S' share capital after the capital increase is DKK 66,129,923 which is made up of 66,129,923 shares of a nominal value of DKK 1 each, corresponding to 66,129,923 votes.

根據2024年2月26日第198號丹麥資本市場法第32條,特此宣佈,增資後的Genmab A/S股本總名義價值爲66,129,923丹麥克朗,由66,129,923股股票組成,每股面值爲1丹麥克朗,相當於66,129,923張選票。

About Genmab
Genmab is an international biotechnology company with a core purpose guiding its unstoppable team to strive towards improving the lives of patients through innovative and differentiated antibody therapeutics. For 25 years, its passionate, innovative and collaborative team has invented next-generation antibody technology platforms and leveraged translational, quantitative, and data sciences, resulting in a proprietary pipeline including bispecific T-cell engagers, next-generation immune checkpoint modulators, effector function enhanced antibodies, and antibody-drug conjugates. To help develop and deliver novel antibody therapies to patients, Genmab has formed 20+ strategic partnerships with biotechnology and pharmaceutical companies. By 2030, Genmab's vision is to transform the lives of people with cancer and other serious diseases with knock-your-socks-off (KYSO) antibody medicines.

關於 Genmab
Genmab 是一家國際生物技術公司,其核心目標是指導其不可阻擋的團隊努力通過創新的差異化抗體療法改善患者的生活。25年來,其充滿激情、富有創新精神和協作精神的團隊發明了下一代抗體技術平台,並利用了轉換、定量和數據科學,形成了包括雙特異性T細胞參與劑、下一代免疫檢查點調節劑、效應器功能增強抗體和抗體藥物偶聯物在內的專有產品線。爲了幫助開發和向患者提供新型抗體療法,Genmab已與生物技術和製藥公司建立了20多個戰略合作伙伴關係。到2030年,Genmab 的願景是通過 knocks-off(KYSO)來改變癌症和其他嚴重疾病患者的生活)抗體藥物。

Established in 1999, Genmab is headquartered in Copenhagen, Denmark with locations in Utrecht, the Netherlands, Princeton, New Jersey, U.S., and Tokyo, Japan. For more information, please visit Genmab.com and follow us on LinkedIn and X.

Genmab 成立於 1999 年,總部位於丹麥哥本哈根,在荷蘭烏得勒支、美國新澤西州普林斯頓和日本東京設有分支機構。欲了解更多信息,請訪問 Genmab.com 並關注我們 領英X

Contact:
Marisol Peron, Senior Vice President, Global Communications & Corporate Affairs
T: +1 609 524 0065; E: mmp@genmab.com

聯繫人:
Marisol Peron,全球傳播與企業事務高級副總裁
T: +1 609 524 0065;E: mmp@genmab.com

Andrew Carlsen, Vice President, Head of Investor Relations
T: +45 3377 9558; E: acn@genmab.com

This Company Announcement contains forward looking statements. The words "believe," "expect," "anticipate," "intend" and "plan" and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with preclinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products or technologies obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab's most recent financial reports, which are available on
and the risk factors included in Genmab's most recent Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov. Genmab does not undertake any obligation to update or revise forward looking statements in this Company Announcement nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law.
Genmab A/S and/or its subsidiaries own the following trademarks: Genmab; the Y-shaped Genmab logo; Genmab in combination with the Y-shaped Genmab logo; HuMax; DuoBody; HexaBody; DuoHexaBody, HexElectand KYSO.

安德魯·卡爾森,副總裁,投資者關係主管
T: +45 3377 9558;E: acn@genmab.com

本公司公告包含前瞻性陳述。“相信”、“期望”、“預測”、“打算” 和 “計劃” 等詞以及類似的表述表示前瞻性陳述。實際結果或業績可能與此類陳述所表達或暗示的任何未來業績或業績存在重大差異。可能導致我們的實際結果或業績出現重大差異的重要因素包括與產品的臨床前和臨床開發相關的風險、與臨床試驗結果和進行相關的不確定性,包括不可預見的安全問題、與產品製造相關的不確定性、我們的產品缺乏市場認可度、我們無法管理增長、與我們的業務領域和市場相關的競爭環境、我們無法吸引和留住合格的人員,我們的專利和專有權利、我們與附屬實體的關係、可能使我們的產品或技術過時的技術變化和發展以及其他因素的不可執行性或缺乏保護。有關這些風險的進一步討論,請參閱Genmab最新財務報告中的風險管理部分,這些報告可在以下網址查閱
以及 Genmab 最新的 20-F 表年度報告和其他文件中包含的風險因素 與美國證券交易委員會 (SEC) 聯繫,可在以下網址獲得 www.sec.gov。除非法律要求,否則Genmab不承擔任何義務更新或修改本公司公告中的前瞻性陳述,也不承擔任何義務確認此類陳述以反映發佈之日後的後續事件或情況或與實際業績有關的事件或情況。
Genmab A/S 和/或其子公司擁有以下商標:Genmab; Y 形的 Genmab 徽標; Genmab 與 Y 形的 Genmab 徽標相結合; HuMax; duoBody; HexAbody; duoHexBody,Hexelect還有 KYSO

Company Announcement no. 35
CVR no. 2102 3884
LEI Code 529900MTJPDPE4MHJ122

公司公告第 35 號
CVR 號 2102 3884
LEI Code 529900MTJPDPE4MHJ122

Genmab A/S
Carl Jacobsens Vej 30
2500 Valby
Denmark

Genmab A/S
卡爾·雅各布森的 Vej 30
2500 Valby
丹麥

Attachment

附件

  • 070524_CA35_FINAL_Warrant Exercise
  • 070524_ca35_final_Warrant 演習

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論